US Bancorp’s Immuneering IMRX Stock Holding History

US Bancorp’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-228	Closed	-$347	–	4242
2025 Q1	$347	Buy	+228	New	+$414	﹤0.01%	4067

Other funds holding IMRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Southport Management Wilson, Wyoming $28.6M AUM 41.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

US Bancorp's IMRX Position: Q2 2025 in Review

US Bancorp sold out of Immuneering (IMRX) in Q2 2025, closing a stake of 228 shares — an estimated $347 sold.

US Bancorp first reported a position in IMRX in Q1 2025 and held it in 1 quarter. The position peaked at $347 in Q1 2025. 39 funds tracked by Wall St. Rank hold IMRX as of Q2 2025.

US Bancorp reported no remaining Immuneering position as of Q2 2025 after selling out during the quarter.
US Bancorp sold 228 Immuneering shares in Q2 2025, an estimated $347.
US Bancorp first reported a position in Immuneering in Q1 2025 and held it in 1 quarter.
US Bancorp's Immuneering position peaked at $347 in Q1 2025.
39 funds tracked by Wall St. Rank held Immuneering as of Q2 2025.

Based on US Bancorp's 13F filing for Q2 2025, filed 24 Jul 2025.